4.4 Article

Lipoprotein changes in HIV-infected antiretroviral-naive individuals after starting antiretroviral therapy: ACTG Study A5152s

期刊

JOURNAL OF CLINICAL LIPIDOLOGY
卷 2, 期 6, 页码 464-471

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacl.2008.08.442

关键词

Antiretroviral therapy; Cardiovascular risk; Clinical trial; Human immunodeficiency virus; Lipids; Lipoproteins

资金

  1. National Institute of Allergy and Infectious Diseases
  2. National Heart, Lung, and Blood Institute
  3. Abbott Laboratories
  4. Bristol-Myers Squibb Company
  5. National Institutes of Health (NIH) [AI069424, AI56933, AI069428, AI25859, HL72711, RR00750, RR000750, AI069513, AI34853, RR16467, MD000173, AI069471, AI38855, AI068634, RR16176, AI25915, AI69432, AI38558, AI068636]

向作者/读者索取更多资源

BACKGROUND: Dyslipidemia is a frequent complication of antiretroviral therapy (ART) for patients with human immunodeficiency virus infection (HIV). The effects of ART on lipoproteins are less well-understood, and have not been investigated in a prospective study where assignment to ART is randomized. OBJECTIVE: To evaluate the effects of three class-sparing ART regimens on lipids and lipoproteins. METHODS: This was a substudy of a prospective, multicenter study of treatment-naive HIV-infected individuals randomly assigned to receive a regimen of nucleoside reverse transcriptase inhibitors (NRTIs) + the non-nucleoside reverse transcriptase inhibitor efavirenz, NRTIs + the protease inhibitor lopinavir/ritonavir, or a NRTI-sparing regimen of efavirenz + lopinavir/ritonavir. Lipoproteins were measured by nuclear magnetic resonance spectroscopy. RESULTS: Among the 82 participants, total and small low-density lipoprotein concentrations increased by a median of 152 nmol/L (interquartile range, -49 to +407 nmol/L; P < 0.01) and 130 nmol/L (interquartile range, -98 to +417 nmol/L; P < 0.01), respectively, especially in the arms containing lopinavir/ritonavir (P-KW < 0.04). Very-low-density lipoproteins also increased (P < 0.01), with a larger increase in the arms that contained lopinavir/ritonavir (P = 0.022). High-density lipoproteins increased by a median of 6.0 nmol/L (interquartile range, 2.8-10.4 nmol/L; P < 0.01), but differences between anus were not significant (P-KW = 0.069). Changes were not related to changes in markers of insulin/glucose metabolism. CONCLUSIONS: Total and small low-density lipoprotein concentrations increased, especially in the arms containing lopinavir/ritonavir, as did increases in total very-low-density lipoproteins. Adverse changes were especially prominent in the arm with efavirenz + lopinavir/ritonavir. (C) 2008 National Lipid Association. Published by Elsevier Inc. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据